PI3K/mTOR Inhibitor-13 sodium

• CAT Number: I041699
• CAS Number: 2361009-23-4
• Molecular Formula: C20H13F2N5NaO3S
• Molecular Weight: 464.40
• Purity: ≥95%
• InChI: InChI=1S/C20H13F2N5O3S.Na/c1-30-20-17(26-31(28,29)19-3-2-15(21)8-16(19)22)6-13(10-24-20)12-4-5-27-18(7-12)14(9-23)11-25-27;/h2-8,10-11,26H,1H3
• InChIKey: AUGQORMNSLXDDP-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=N1)C2=CC3=C(C=NN3C=C2)C#N)NS(=O)(=O)C4=C(C=C(C=C4)F)F.[Na]

PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF)[1][2].
PI3K/mTOR Inhibitor-13 sodium (Compound A) (0-2 µM; 48 h) inhibits the proliferation of HFL1 cells with dose-dependent manner[1].
Pharmacokinetic (PK) parameters of PI3K/mTOR Inhibitor-13 sodium[2]

Species
Administration manner
Dose (mg/kg)
T1/2 (h)
AUClast (ng•h/mL)
Cl/F (L/h/kg)
Vss (L/kg)
F (%)

Rat
Intravenous injection
2
2.77
7069
0.29
0.85
94.75

Mice
Intravenous injection
1
5.45
57059
0.02
0.13
79.3

Dog
Intravenous injection
1
0.67
3672
0.27
0.23
108.5

Monkey
Intravenous injection
1
9.70
5978
0.16
0.92
59.8

Reference

[1]. Cao S, et al. Pharmaceutical combination or pharmaceutical composition for treatment of fibrotic diseases. World Intellectual Property Organization. WO2020078445.

[2]. Xi N, et al. Aromatic heterocyclic compounds, pharmaceutical composition containing compounds and application of pharmaceutical composition.China.CN103965199.